To verify the role of cholesterol in METTL3-induced NAFLD-HCC, we treated orthotopic NAFLD-HCC overexpressing METTL3 with simvastatin, a cholesterol biosynthesis inhibitor. Here, METTL3 is linked to metabolic dysfunction-associated steatotic liver disease.